# UNH — baseline

## Metadata

ticker: UNH
arm: baseline
judge_prompt_version: v2
context_sha256: 6eecc7b212b98593e0438643727fa57a74ec08799dddcf6c62e296d491c681a8
llm_calls: 7
llm_endpoints: anthropic
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 201, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.638, "latency_s_total": 2.638, "parse_failure": 0, "prompt_tokens": 3273, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 368, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 5.043, "latency_s_total": 5.043, "parse_failure": 0, "prompt_tokens": 3261, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 205, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.464, "latency_s_total": 2.464, "parse_failure": 0, "prompt_tokens": 813, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 145, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.012, "latency_s_total": 2.012, "parse_failure": 0, "prompt_tokens": 806, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 213, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.459, "latency_s_total": 2.459, "parse_failure": 0, "prompt_tokens": 442, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 128, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 1.931, "latency_s_total": 1.931, "parse_failure": 0, "prompt_tokens": 283, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 1211, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 17.543, "latency_s_total": 17.543, "parse_failure": 0, "prompt_tokens": 1788, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "UNH",
  "company_name": "UnitedHealth Group Incorporated",
  "current_price": 375.98,
  "currency": "USD",
  "market_cap": 337477697536.0,
  "pe_ratio": 24.194338,
  "forward_pe": 16.628786,
  "week_52_high": 461.62,
  "week_52_low": 255.97,
  "financial_currency": "USD",
  "revenue": 450525986816.0,
  "net_income": 14122000384.0,
  "profit_margin_pct": 3.14,
  "dividend_yield": 2.47,
  "sector": "Healthcare",
  "industry": "Healthcare Plans"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-02",
    "summary": "ITEM 1A. RISK FACTORS CAUTIONARY STATEMENTS The statements, estimates, projections or outlook contained in this Annual Report on Form 10-K include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). When used in this Annual Report on Form 10-K and in future filings by us with the SEC, in our news releases, presentations to securities analysts or investors, and in oral statements made by or with the approval of one of our executive officers, the words \u201cbelieve,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cestimate,\u201d \u201canticipate,\u201d \u201cforecast,\u201d \u201coutlook,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201cshould\u201d or similar words or phrases are intended to identify such forward-looking statements. These statements are intended to take advantage of the \u201csafe harbor\u201d provisions of the PSLRA"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-10",
    "summary": "ITEM 1A. RISK FACTORS In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, \u201cRisk Factors\u201d of our 2025 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2025 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. There have been no material changes to the risk factors as disclosed in our 2025 10-K. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS Issuer Purchases of Equity Securities (a) Second Quarter 2026 For the Month Ended Total Number of Shares Pu"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] I cannot provide a summary of the latest 10-K and 10-Q based on the context provided. The information given contains only excerpts from the Risk Factors section of a 10-K filing for UNH (UnitedHealth Group), specifically focusing on risks related to medical cost management, technology systems, cybersecurity, and data integrity.

To provide a comprehensive summary of the latest 10-K and 10-Q filings, I would need access to additional sections such as:

- Management's Discussion and Analysis (MD&A)
- Financial statements and results of operations
- Business overview and segment performance
- Liquidity and capital resources
- Recent developments and highlights

The context provided only addresses risk disclosures, which represent just one portion of these regulatory filings. A complete summary would require information from multiple sections of both documents to accurately represent the company's financial performance, operational results, and overall business status.

RAG — RISK FACTORS:
[From Pinecone cache] # Primary Risk Factors Disclosed

The company discloses several significant risk factors affecting its business:

## Medical Cost Management and Pricing Risks
The company assumes medical and administrative costs through risk-based benefit products, which constitute nearly 80% of total consolidated revenues. Key risks include the inability to accurately estimate, price for, and manage medical costs. Small differences between predicted and actual medical costs can result in significant financial impacts. Various factors may cause actual costs to exceed estimates, including medical cost inflation, increased service utilization, provider billing intensity, unexpected population differences, new or costly drugs, pandemics, climate change effects, and regulatory changes. Cost increases cannot typically be recovered through higher premiums during fixed contract periods.

## Data Integrity and Information Systems Risks
The business depends heavily on the accuracy and availability of data used to serve members, customers, and healthcare professionals. Risks include inaccurate or unreliable data, failures in health and wellness products, difficulty attracting customers, problems with medical cost estimation and pricing, fraud detection challenges, and regulatory sanctions. The company must maintain and protect data integrity while managing rapid technological changes, including artificial intelligence and generative AI applications.

## Cybersecurity and Data Security Risks
The company routinely processes large amounts of protected personal information and proprietary data. It faces regular cyberattack attempts and has previously experienced security incidents, including a cyberattack on its Change Healthcare business in 2024. Risks include operational disruptions, unauthorized access to sensitive information, ransomware, system failures, and potential litigation and regulatory penalties.

## Healthcare Provider Relationship Risks
The company's business depends on maintaining satisfactory relationships with healthcare payers, physicians, hospitals, and other service providers.

## Pre-written sections (judge input)

### Financial Health

UnitedHealth Group trades at $375.98 with a substantial market capitalization of $337.5 billion, reflecting its position as a healthcare industry leader. The company generated $450.5 billion in revenue with a net profit margin of 3.14%, yielding $14.1 billion in net income, demonstrating solid operational scale despite modest profitability typical of managed care. The current P/E ratio of 24.2x appears elevated relative to the forward P/E of 16.6x, suggesting market expectations for earnings growth or potential valuation compression. With a 2.47% dividend yield and recent 52-week trading range of $255.97–$461.62, UNH exhibits both volatility and investor confidence in its long-term prospects. Overall, the company presents a financially stable profile with strong revenue generation, though investors should monitor margin pressures inherent in the healthcare plans sector.

### Recent Developments

UnitedHealth Group's most recent SEC filings show no material changes to previously disclosed risk factors as of the second quarter 2026, suggesting operational stability in the healthcare plans segment. The company continues to execute share repurchase programs, with activity noted in Q2 2026, supporting shareholder returns alongside its 2.47% dividend yield. With a forward P/E of 16.6x and strong revenue base of $450.5 billion, UNH appears reasonably valued relative to its growth prospects, though investors should monitor regulatory developments in the healthcare sector and execution on cost management initiatives given the modest 3.14% profit margin.

### SEC Filing Highlights

Based on available information, UnitedHealth Group's recent SEC filings emphasize significant operational risks requiring management attention, including medical cost management challenges, technology system vulnerabilities, and cybersecurity threats. The company has disclosed material risks related to data integrity and the potential impact of system failures on business operations. However, comprehensive details regarding financial performance, revenue trends, and segment results would require access to the full MD&A and financial statements sections of the most recent 10-K or 10-Q filing. For a complete investment analysis, review of the complete regulatory documents is recommended.

### Risk Factors

• **Medical Cost Management and Pricing Risk**: With risk-based benefit products representing ~80% of revenues, the company faces significant exposure to medical cost inflation, utilization increases, and unexpected population health changes. Small variances between predicted and actual medical costs can materially impact earnings, and cost increases cannot typically be recovered through higher premiums during fixed contract periods.

• **Cybersecurity and Data Security Risk**: The company processes large volumes of protected personal information and faces regular cyberattack attempts. A 2024 cyberattack on its Change Healthcare business demonstrated operational vulnerability; future incidents could result in system disruptions, unauthorized data access, litigation, and regulatory penalties.

• **Data Integrity and Information Systems Risk**: Business operations depend on accurate, reliable data for member services and medical cost estimation. System failures, data inaccuracies, or difficulties managing rapid technological changes (including AI/generative AI) could impair pricing accuracy, fraud detection, and regulatory compliance.

## Audited (Exec Summary + Outlook)

### Executive Summary
UnitedHealth Group is a healthcare industry leader operating at massive scale, generating $450.5 billion in revenue and $14.1 billion in net income, with a market capitalization of $337.5 billion that reflects its dominant position in managed care. The stock is notable now because it trades well below its 52-week high of $461.62 at a current price of $375.98, while the gap between its current P/E of 24.2x and forward P/E of 16.6x signals that the market is pricing in meaningful earnings growth — a thesis that hinges on the company's ability to control medical costs against a backdrop of elevated operational and cybersecurity risk. The single most important near-term variable is medical cost management: given that risk-based benefit products represent approximately 80% of revenues and that small variances in medical costs can materially impact earnings, the trajectory of medical cost ratios will be the primary determinant of whether the forward earnings implied by the valuation gap are achievable.

### Outlook
The directional outlook for UNH is **cautiously constructive**, with the investment thesis resting on a narrow but meaningful set of variables that could shift sentiment materially in either direction. On the tailwind side, continued share repurchase activity, a supportive dividend yield, and the significant gap between the current and forward P/E suggest the market anticipates earnings improvement — a scenario that would be reinforced by disciplined medical cost management, successful premium repricing cycles, and stable regulatory conditions. On the headwind side, the company's thin net profit margin leaves little room for error: any acceleration in medical cost inflation, elevated utilization trends, or adverse population health developments could compress earnings and challenge the forward valuation implied by current pricing. Investors should closely watch the trajectory of the medical cost ratio across reporting periods, the pace and outcome of any regulatory developments affecting the healthcare plans sector, and management's progress in hardening its technology and cybersecurity infrastructure following the 2024 Change Healthcare incident. A deterioration in any of these areas — particularly a sustained rise in medical costs or a significant new cybersecurity event — would weaken the thesis; conversely, evidence of improving cost discipline and a benign regulatory environment would support a more constructive view.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically audit every quantitative, positional, and forward-looking specific claim in the Executive Summary and Outlook sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "generating $450.5 billion in revenue"
LABEL: SUPPORTED
REASON: Source data shows revenue of $450,525,986,816, which rounds to $450.5 billion, consistent with the Pre-written Financial Health section.

---

CLAIM: "$14.1 billion in net income"
LABEL: SUPPORTED
REASON: Source data shows net income of $14,122,000,384, which rounds to $14.1 billion, consistent with the Pre-written Financial Health section.

---

CLAIM: "market capitalization of $337.5 billion"
LABEL: SUPPORTED
REASON: Source data shows market_cap of $337,477,697,536, which rounds to $337.5 billion.

---

CLAIM: "trades well below its 52-week high of $461.62"
LABEL: SUPPORTED
REASON: Source data confirms 52-week high of $461.62 and current price of $375.98; $375.98 is $85.64 below $461.62, arithmetically confirming "well below."

---

CLAIM: "at a current price of $375.98"
LABEL: SUPPORTED
REASON: Source data explicitly states current_price of $375.98.

---

CLAIM: "current P/E of 24.2x"
LABEL: SUPPORTED
REASON: Source data shows pe_ratio of 24.194338, which rounds to 24.2x.

---

CLAIM: "forward P/E of 16.6x"
LABEL: SUPPORTED
REASON: Source data shows forward_pe of 16.628786, which rounds to 16.6x.

---

CLAIM: "risk-based benefit products represent approximately 80% of revenues"
LABEL: SUPPORTED
REASON: The RAG Risk Factors section explicitly states "risk-based benefit products, which constitute nearly 80% of total consolidated revenues," and this is echoed in the Pre-written Risk Factors section.

---

CLAIM: "small variances in medical costs can materially impact earnings"
LABEL: SUPPORTED
REASON: The RAG Risk Factors section explicitly states "Small differences between predicted and actual medical costs can result in significant financial impacts."

---

**OUTLOOK**

---

CLAIM: "significant gap between the current and forward P/E"
LABEL: SUPPORTED
REASON: Current P/E is 24.2x and forward P/E is 16.6x per source data, a gap of approximately 7.6x, which is arithmetically a significant gap.

---

CLAIM: "thin net profit margin"
LABEL: SUPPORTED
REASON: Source data shows profit_margin_pct of 3.14%, which is explicitly described as a "modest 3.14% profit margin" in the Pre-written Recent Developments section; 3.14% is objectively thin.

---

CLAIM: "the 2024 Change Healthcare incident"
LABEL: SUPPORTED
REASON: The RAG Risk Factors section explicitly references "a cyberattack on its Change Healthcare business in 2024," and this is echoed in the Pre-written Risk Factors section.

---

CLAIM: "continued share repurchase activity"
LABEL: SUPPORTED
REASON: The 10-Q filing summary references "Issuer Purchases of Equity Securities" and "Second Quarter 2026" share repurchase activity, and the Pre-written Recent Developments section confirms "share repurchase programs, with activity noted in Q2 2026."

---

CLAIM: "a supportive dividend yield"
LABEL: SUPPORTED
REASON: Source data shows dividend_yield of 2.47%, which is a positive yield; the Pre-written sections describe it as supportive of shareholder returns.

---

*No additional specific quantitative figures, price targets, thresholds, ratios, named product milestones, or forward-looking numbers appear in the Outlook section beyond those already audited above.*
